Performance Profile and Carcass Characteristics of Steers Fed Optaflexx

An experiment evaluated the live BW response of steers being fed Optaflexx for various durations. The design consisted of two Optaflexx levels (0 vs. 200 mg per steer daily) and two Optaflexx feeding durations (28 or 42 days immediately prior to slaughter). However, Optaflexx was started on the same day (day 151 of the feeding period). Feeding 200 mg/steer daily of Optaflexx significantly (P\u3c0.01) improved final BW, ADG, and F:G compared to controls. Feeding 200 mg /steer daily of Optaflexx provided 16.4 and 18.8 lb of added BW above controls for the 28 and 42 feeding duration, respectively, but most (approximately 87%) of this weight gain was within the first 28 days of the time that Optaflexx was fed

Performance Profile and Carcass Characteristics of Steers Fed Optaflexx

An experiment evaluated the live BW response of steers being fed Optaflexx for various durations. The design consisted of two Optaflexx levels (0 vs. 200 mg per steer daily) and two Optaflexx feeding durations (28 or 42 days immediately prior to slaughter). However, Optaflexx was started on the same day (day 151 of the feeding period). Feeding 200 mg/steer daily of Optaflexx significantly (P\u3c0.01) improved final BW, ADG, and F:G compared to controls. Feeding 200 mg /steer daily of Optaflexx provided 16.4 and 18.8 lb of added BW above controls for the 28 and 42 feeding duration, respectively, but most (approximately 87%) of this weight gain was within the first 28 days of the time that Optaflexx was fed

Kleine bedrijven hebben weinig vertrouwen in de toekomst van het bedrijf

Het vertrouwen van boeren en tuinders in de toekomst van hun bedrijf is een graadmeter voor de economische gesteldheid van de agrarische sector. Een groot deel van de agrariërs ziet de toekomst op korte termijn optimistisch tegemoet. Op lange termijn hebben ondernemers op grotere bedrijven meer vertrouwen in de toekomst dan die op kleinere bedrijve

The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects

Thrombosis and Hemostasi

Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects

Phenotypic characterization of congenital platelet defects (CPDs) could help physicians recognize CPD subtypes and can inform on prognostic implications. We report the analyses of the bleeding phenotype and diagnostic characteristics of a large cohort of adult patients with a confirmed CPD. A total of 96 patients were analyzed and they were classified as Glanzmann thrombasthenia, Bernard-Soulier syndrome, dense granule deficiency, defects in the ADP or thromboxane A2 (TxA2) pathway, isolated thrombocytopenia or complex abnormalities. The median ISTH-BAT bleeding score was nine (IQR 5-13). Heavy menstrual bleeding (HMB) (80%), post-partum hemorrhage (74%), post-operative bleeds (64%) and post-dental extraction bleeds (57%) occurred most frequently. Rare bleeding symptoms were bleeds from the urinary tract (4%) and central nervous system (CNS) bleeds (2%). Domains with a large proportion of severe bleeds were CNS bleeding, HMB and post-dental extraction bleeding. Glanzmann thrombasthenia and female sex were associated with a more severe bleeding phenotype

Congenital platelet disorders and health status-related quality of life

Background: Patients with congenital blood platelet disorders (CPDs) demonstrate a predominantly mucocutaneous bleeding tendency. Repeated bleeds throughout life can have a significant impact on health status-related quality of life (HR-QoL), but few studies have investigated HR-QoL in patients with CPDs. Objectives: To determine HR-QoL in patients with suspected or confirmed CPDs as compared with the general Dutch population and to assess the association between bleeding phenotype and HR-QoL. Methods: Data were derived from the Thrombocytopathy in the Netherlands (TiN) study, a cross-sectional study of individuals suspected for a congenital platelet defect. TiN patients with an increased ISTH Bleeding Assessment Tool (ISTH-BAT) score (>3 in men and > 5 in women) were included for analysis. HR-QoL was assessed with the Short Form (SF)-36 survey. Bleeding symptoms were evaluated with the ISTH-BAT, resulting in a bleeding score. Results: One hundred fifty-six patients were analyzed, of whom 126 (81%) were women. Sixty-two patients (40%) had a confirmed CPD. Compared to the general Dutch population, patients with a suspected or confirmed CPD reported decreased physical functioning, limitations in daily activities due to physical health problems, limitations in social activities, decreased energy levels and fatigue, pain, and lower general health status. HR-QoL was not correlated with the ISTH-BAT score and was similar in patients with a confirmed CPD and those in whom a CPD could not be diagnosed. Conclusion: A bleeding tendency in patients with a suspected or confirmed CPD significantly impacts HR-QoL, independent of a confirmed explanatory diagnosis

Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency

Background: δ-storage pool disease (δ-SPD) is a bleeding disorder characterized by a reduced number of platelet-dense granules. The diagnosis of δ-SPD depends on the measurement of platelet ADP content, but this test is time consuming and requires a relatively large blood volume. Flow cytometric analysis of platelet mepacrine uptake is a potential alternative, but this approach lacks validation, which precludes its use in a diagnostic setting. Objectives: To evaluate the performance of platelet mepacrine uptake as a diagnostic test for δ-SPD. Patients/Methods: Mepacrine fluorescence was determined with flow cytometry before and after platelet activation in 156 patients with a suspected platelet function disorder and compared with platelet ADP content as a reference test. Performance was analyzed with a receiver operating characteristic (ROC) curve. Results: Eleven of 156 patients had δ-SPD based on platelet ADP content. Mepacrine fluorescence was inferior to platelet ADP content in identifying patients with δ-SPD, but both mepacrine uptake (area under the ROC curve [AUC] 0.87) and mepacrine release after platelet activation (AUC 0.80) had good discriminative ability. In our tertiary reference center, mepacrine uptake showed high negative predicitive value (97%) with low positive predictive value (35%). Combined with a negative likelihood ratio of 0.1, these data indicate that mepacrine uptake can be used to exclude δ-SPD in patients with a bleeding tendency. Conclusion: Mepacrine fluorescence can be used as a screening tool to exclude δ-SPD in a large number of patients with a suspected platelet function disorder